Pharmacology: Pharmacodynamics: Mechanism of action:
Mirabegron (Betmiga) is a potent and selective beta 3-adrenoceptor agonist. Mirabegron (Betmiga) showed relaxation of bladder smooth muscle in rat and human isolated tissue, increased cyclic adenosine monophosphate (cAMP) concentrations in rat bladder tissue and showed a bladder relaxant effect in rat urinary bladder function models. Mirabegron (Betmiga) increased mean voided volume per micturition and decreased the frequency of non-voiding contractions, without affecting voiding pressure, or residual urine in rat models of bladder overactivity. In a monkey model, mirabegron showed decreased voiding frequency. These results indicate that mirabegron enhances urine storage function by stimulating beta 3-adrenoceptors in
During the urine storage phase, when urine accumulates in the bladder, sympathetic nerve stimulation predominates. Noradrenaline is released from nerve terminals, leading predominantly to beta adrenoceptor activation in the bladder musculature, and hence bladder smooth muscle relaxation. During the urine voiding phase, the bladder is predominantly under parasympathetic nervous system control. Acetylcholine, released from pelvic nerve terminals, stimulates cholinergic M2 and M3 receptors, inducing bladder contraction. The activation of the M2 pathway also inhibits beta 3-adrenoceptor induced increases in cAMP. Therefore beta 3-adrenoceptor stimulation should not interfere with the voiding process. This was confirmed in rats with partial urethral obstruction, where mirabegron decreased the frequency of non-voiding contractions without affecting the voided volume per micturition, voiding pressure, or residual urine volume.
Urodynamics Mirabegron (Betmiga) at doses of 50 mg and 100 mg once daily for 12 weeks in men with lower urinary tract symptoms (LUTS) and bladder outlet obstruction (BOO) showed no effect on cystometry parameters and was safe and well tolerated. The effects of mirabegron on maximum flow rate and detrusor pressure at maximum flow rate were assessed in this urodynamic study consisting of 200 male patients with LUTS and BOO. Administration of mirabegron at doses of 50 mg and 100 mg once daily for 12 weeks did not adversely affect the maximum flow rate or detrusor pressure at maximum flow rate.
In this study in male patients with LUTS/BOO, the adjusted mean (SE) change from baseline to end of treatment in post void residual volume (mL) was 0.55 (10.702), 17.89 (10.190), 30.77 (10.598) for the placebo, Mirabegron (Betmiga) 50 mg and Mirabegron (Betmiga) 100 mg treatment groups.
Effect on QT interval: Mirabegron (Betmiga) at doses of 50 mg or 100 mg had no effect on the QT interval individually corrected for
heart rate (QTcI interval) when evaluated either by sex or by the overall group.
A thorough QT (TQT) study (n = 164 healthy male and n = 153 healthy female volunteers with a mean age of 33
years) evaluated the effect of repeat oral dosing of Mirabegron (Betmiga) at the indicated dose (50 mg once
daily) and two supra-therapeutic doses (100 and 200 mg once daily) on the QTcI interval. The supra-therapeutic
doses represent approximately 2.6- and 6.5-fold the exposure of the therapeutic dose, respectively. A single
400 mg dose of moxifloxacin was used as a positive control. Each dose level of Mirabegron (Betmiga) and
moxifloxacin was evaluated in separate treatment arms each including placebo-control (parallel cross-over
design). For both males and females administered mirabegron at 50 mg and 100 mg, the upper bound of the
one-sided 95% confidence interval did not exceed 10 msec at any time point for the largest time-matched
mean difference from placebo in the QTcI interval. In females administered Mirabegron (Betmiga) at the 50 mg
dose, the mean difference from placebo on QTcI interval at 5 hours post dose was 3.67 msec (upper bound of
the one-sided 95% CI 5.72 msec). In males, the difference was 2.89 msec (upper bound of the one-sided 95%
CI 4.90 msec). At a Mirabegron (Betmiga) dose of 200 mg, the QTcI interval did not exceed 10 msec at any
time point in males, while in females the upper bound of the one-sided 95% confidence interval did exceed
10 msec between 0.5-6 hours, with a maximum difference from placebo at 5 hours where the mean effect was
10.42 msec (upper bound of the one-sided 95% CI 13.44 msec). Results for QTcF and QTcIf were consistent with
In this TQT study, Mirabegron (Betmiga) increased heart rate on ECG in a dose dependent manner across the
50 mg to 200 mg dose range examined. The maximum mean difference from placebo in heart rate ranged from
6.7 bpm with Mirabegron (Betmiga) 50 mg up to 17.3 bpm with Mirabegron (Betmiga) 200 mg in healthy
Effects on pulse rate and blood pressure in patients with OAB:
In OAB patients (mean age of 59 years) across three 12-week phase 3 double blind, placebo controlled
studies receiving Mirabegron (Betmiga) 50 mg once daily, an increase in mean difference from placebo of
approximately 1 bpm for pulse rate and approximately 1 mm Hg or less in systolic blood pressure/diastolic
blood pressure (SBP/DBP) was observed. Changes in pulse rate and blood pressure are reversible upon
discontinuation of treatment.
Effect on intraocular pressure (IOP):
Mirabegron (Betmiga) 100 mg once daily did not increase IOP in healthy subjects after 56 days of treatment.
In a phase 1 study assessing the effect of mirabegron on IOP using Goldmann applanation tonometry in
310 healthy subjects, a dose of Mirabegron (Betmiga) 100 mg was non-inferior to placebo for the primary
endpoint of the treatment difference in mean change from baseline to day 56 in subject-average IOP; the
upper bound of the two-sided 95% CI of the treatment difference between Mirabegron (Betmiga) 100 mg and
placebo was 0.3 mm Hg.
Clinical efficacy and safety:
Efficacy of Mirabegron (Betmiga) was evaluated in three phase 3 randomized, double blind, placebo controlled, 12-week studies for the treatment of overactive bladder with symptoms of urgency and frequency with or without incontinence. Female (72%) and male (28%) patients with a mean age of 59 years (range 18-95 years) were included. The study population consisted of approximately 48% antimuscarinic treatment naïve patients as well as approximately 52% patients previously treated with antimuscarinic medication. In one study, 495 patients received an active control (tolterodine prolonged release formulation).
The co-primary efficacy endpoints were (1) change from baseline to end of treatment in mean number of incontinence episodes per 24 hours and (2) change from baseline to end of treatment in mean number of micturitions per 24 hours based on a 3-day micturition diary. Mirabegron (Betmiga) demonstrated statistically significant larger improvements compared to placebo for both co-primary endpoints as well as secondary endpoints (see Tables 1 and 2).
Click on icon to see table/diagram/image
Click on icon to see table/diagram/image
Mirabegron (Betmiga) 50 mg once daily was effective at the first measured time point of week 4, and efficacy was maintained throughout the 12-week treatment period. A randomized, active controlled, long term study demonstrated that efficacy was maintained throughout a 1-year treatment period.
Subjective improvement in health-related quality of life measurements: In the three 12-week phase 3 double blind, placebo controlled studies, treatment of the symptoms of OAB with Mirabegron (Betmiga) once daily resulted in a statistically significant improvement over placebo on the following health-related quality of life measures: treatment satisfaction and symptom bother.
Efficacy in patients with or without prior OAB antimuscarinic therapy: Efficacy was demonstrated in patients with and without prior OAB antimuscarinic therapy. In addition Mirabegron (Betmiga) showed efficacy in patients who previously discontinued OAB antimuscarinic therapy due to insufficient effect (see Table 3).
Click on icon to see table/diagram/image
The European Medicines Agency has deferred the obligation to submit the results of studies with Mirabegron (Betmiga) in one or more subsets of the paediatric population in "Treatment of idiopathic overactive bladder" and "Treatment of neurogenic detrusor overactivity" (see Dosage & Administration for information on paediatric use).
After oral administration of Mirabegron (Betmiga) in healthy volunteers Mirabegron (Betmiga) is absorbed to reach peak plasma concentrations (Cmax
) between 3 and 4 hours. The absolute bioavailability increased from 29% at a dose of 25 mg to 35% at a dose of 50 mg. Mean Cmax
and AUC increased more than dose proportionally over the dose range. In the overall population of males and females, a 2-fold increase in dose from 50 mg to 100 mg mirabegron increased Cmax
by approximately 2.9- and 2.6-fold, respectively, whereas a 4-fold increase in dose from 50 mg to 200 mg Mirabegron (Betmiga) increased Cmax
by approximately 8.4- and 6.5-fold. Steady state concentrations are achieved within 7 days of once daily dosing with Mirabegron (Betmiga). After once daily administration, plasma exposure of Mirabegron (Betmiga) at steady state is approximately double that seen after a single dose.
Effect of food on absorption:
Co-administration of a 50 mg tablet with a high-fat meal reduced mirabegron Cmax
and AUC by 45% and 17%, respectively. A low-fat meal decreased Mirabegron (Betmiga) Cmax
and AUC by 75% and 51%, respectively. In the phase 3 studies, Mirabegron (Betmiga) was administered with or without food and demonstrated both safety and efficacy. Therefore, Mirabegron (Betmiga) can be taken with or without food at the recommended dose.
Mirabegron (Betmiga) is extensively distributed. The volume of distribution at steady state (Vss
) is approximately 1670 L. Mirabegron (Betmiga) is bound (approximately 71%) to human plasma proteins, and shows moderate affinity for albumin and alpha-1 acid glycoprotein. Mirabegron (Betmiga) distributes to erythrocytes. In vitro
erythrocyte concentrations of 14
C-mirabegron were about 2-fold higher than in plasma.
Mirabegron (Betmiga) is metabolized via multiple pathways involving dealkylation, oxidation, (direct) glucuronidation, and amide hydrolysis. Mirabegron (Betmiga) is the major circulating component following a single dose of 14
C-mirabegron. Two major metabolites were observed in human plasma; both are phase 2 glucuronides representing 16% and 11% of total exposure. These metabolites are not pharmacologically active.
Based on in vitro
studies, Mirabegron (Betmiga) is unlikely to inhibit the metabolism of co-administered medicinal products metabolized by the following cytochrome P450 enzymes: CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 and CYP2E1 because Mirabegron (Betmiga) did not inhibit the activity of these enzymes at clinically relevant concentrations. Mirabegron (Betmiga) did not induce CYP1A2 or CYP3A. Mirabegron (Betmiga) is predicted not to cause clinically relevant inhibition of OCT-mediated drug transport.
Although in vitro
studies suggest a role for CYP2D6 and CYP3A4 in the oxidative metabolism of Mirabegron (Betmiga), in vivo
results indicate that these isozymes play a limited role in the overall elimination. In vitro
and ex vivo
studies have shown the involvement from butyrylcholinesterase, UGT and possibly alcohol dehydrogenase (ADH) in the metabolism of Mirabegron (Betmiga), in addition to CYP3A4 and CYP2D6.
CYP2D6 polymorphism: In healthy subjects who are genotypically poor metabolisers of CYP2D6 substrates (used as a surrogate for CYP2D6 inhibition), mean Cmax
of a single 160 mg dose of a Mirabegron (Betmiga) IR formulation were 14% and 19% higher than in extensive metabolisers, indicating that CYP2D6 genetic polymorphism has minimal impact on the mean plasma exposure to Mirabegron (Betmiga). Interaction of mirabegron with a known CYP2D6 inhibitor is not expected and was not studied. No dose adjustment is needed for Mirabegron (Betmiga) when administered with CYP2D6 inhibitors or in patients who are CYP2D6 poor metabolisers.
Total body clearance (CLtot
) from plasma is approximately 57 L/h. The terminal elimination half-life (t1/2
) is approximately 50 hours. Renal clearance (CLR
) is approximately 13 L/h, which corresponds to nearly 25% of CLtot
. Renal elimination of Mirabegron (Betmiga) is primarily through active tubular secretion along with glomerular filtration. The urinary excretion of unchanged Mirabegron (Betmiga) is dose-dependent and ranges from approximately 6.0% after a daily dose of 25 mg to 12.2% after a daily dose of 100 mg. Following the administration of 160 mg 14
C-mirabegron to healthy volunteers, approximately 55% of the radiolabel was recovered in the urine and 34% in the faeces. Unchanged mirabegron accounted for 45% of the urinary radioactivity, indicating the presence of metabolites. Unchanged Mirabegron (Betmiga) accounted for the majority of the faecal radioactivity.
and AUC of Mirabegron (Betmiga) and its metabolites following multiple oral doses in elderly volunteers (≥ 65 years) were similar to those in younger volunteers (18-45 years).
and AUC are approximately 40% to 50% higher in females than in males. Gender differences in Cmax
and AUC are attributed to differences in body weight and bioavailability.
The pharmacokinetics of Mirabegron (Betmiga) are not influenced by race.
Following single dose administration of 100 mg Mirabegron (Betmiga) in volunteers with mild renal impairment (eGFR-MDRD 60 to 89 mL/min/1.73 m2
), mean Mirabegron (Betmiga) Cmax
and AUC were increased by 6% and 31% relative to volunteers with normal renal function. In volunteers with moderate renal impairment (eGFR-MDRD 30 to 59 mL/min/1.73 m2
and AUC were increased by 23% and 66%, respectively. In volunteers with severe renal impairment (eGFR-MDRD 15 to 29 mL/min/1.73 m2
), mean Cmax
and AUC values were 92% and 118% higher. Mirabegron (Betmiga) has not been studied in patients with end stage renal disease (GFR <15 mL/min/1.73 m2
or patients requiring haemodialysis).
Following single dose administration of 100 mg Mirabegron (Betmiga) in volunteers with mild hepatic impairment (Child-Pugh Class A), mean Mirabegron (Betmiga) Cmax
and AUC were increased by 9% and 19% relative to volunteers with normal hepatic function. In volunteers with moderate hepatic impairment (Child-Pugh Class B), mean Cmax
and AUC values were 175% and 65% higher. Mirabegron (Betmiga) has not been studied in patients with severe hepatic impairment (Child-Pugh Class C).
Toxicology: Preclinical safety data:
Pre-clinical studies have identified target organs of toxicity that are consistent with clinical observations.
Transient increases in liver enzymes and hepatocyte changes (necrosis and decrease in glycogen particles) were seen in rats. An increase in heart rate was observed in rats, rabbits, dogs and monkeys. Genotoxicity and carcinogenicity studies have shown no genotoxic or carcinogenic potential in vivo
No effects on fertility were seen at sub-lethal doses [human equivalent dose was 19-fold higher than the maximum human recommended dose (MHRD)]. The main findings in rabbit embryofetal development studies included malformations of the heart (dilated aorta, cardiomegaly) at systemic exposures 36-foldhigher than observed at the MHRD. In addition, malformations of the lung (absent accessory lobe of the lung) and increased post-implantation loss were observed in the rabbit at systemic exposures 14-fold higher than observed at the MHRD, while in the rat reversible effects on ossification were noted (wavy ribs, delayed ossification, decreased number of ossified sternebrae, metacarpi or metatarsi) at systemic exposures 22-fold higher than observed at the MHRD. The observed embryo fetal toxicity occurred at doses associated with maternal toxicity. The cardiovascular malformations observed in the rabbit were shown to be mediated via activation of the beta 1-adrenoceptor.
Pharmacokinetic studies performed with radio-labelled Mirabegron (Betmiga) have shown that the parent compound and/or its metabolites are excreted in the milk of rats at levels that were approximately 1.7-fold higher than plasma levels at 4 hours post administration (see Use in Pregnancy & Lactation).